Arcturus Q1 net income $50.8M ($1.87 EPS) vs loss year ago; NDA filed for COVID vaccine ARCT-154 in Japan

Arcturus Therapeutics Holdings Inc.

2023-Q1 EPS reported $1.87 revenue$80,285,000

Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.
NDA for ARCT-154 (COVID-19 vaccine) submitted in Japan by Meiji Seika Pharma; potential approval later 2023.
Cash $330.1M; long-term debt eliminated; expects $90M AR collection in Q2; runway extended into early 2026.
ARCT-032 Phase 1 enrollment complete; expansion to CF patients planned Q3 2023. ARCT-810 Phase 2 interim data on track for later 2023.
Received $23.6M advance from CSL Seqirus for manufacturing and supply of ARCT-154 in April.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $80.3 million.

Period: first quarter ended March 31, 2023
Revenue: $80.3 million
Result: reported results

Exact text from the filing

Total revenue for the three months ended March 31, 2023, was $80.3 million

View on SEC.gov

Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-000686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.